Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06359847

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of ST-1898 Tablets in Patients With Locally Advanced or Metastatic RAIR-DTC After Failure of at Least First-line TKI Systemic Therapy

Sponsor: Beijing Scitech-Mq Pharmaceuticals Limited

Conditions Differentiated Thyroid Carcinoma

Interventions ST-1898 tablets

Updated 4 times since 2024 Last updated: Aug 22, 2025 Started: Nov 15, 2023 Primary completion: Dec 31, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Differentiated Thyroid Carcinoma and is currently actively recruiting participants. Beijing Scitech-Mq Pharmaceuticals Limited leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Nov 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Scitech-Mq Pharmaceuticals Limited

Data source: Beijing Scitech-Mq Pharmaceuticals Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China